# US 2020/0368278 A1 · Compositions and methods for cell targeting therapies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0368278 A1
- Document ID: US20200368278A1
- Status: Published application
- Kind: A1
- Application number: 16/614,691
- Filed: 2018-05-18
- Published: 2020-11-26
- Earliest claimed: 2017-05-18
- Assignees: UMC Utrecht Holding B.V.
- Applicants: Umc Utrecht Holding B.V.
- Inventors: Jürgen Herbert Ernst KUBALL; Zsolt SEBESTYEN; Dennis BERINGER; Anna VYBOROVA
- Web page: https://patentgrep.com/patent/US20200368278A1

## CPC

- A61K 38/17: from animals; from humans {(enzyme inhibitors A61K38/005)}
- A61K 38/1774: {Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)}
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/30: characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K 40/32: T-cell receptors [TCR]
- A61K 40/421: {Immunoglobulin superfamily}
- A61K 40/4253: {GTPases, e.g. Ras or Rho}
- A61P 35/00: Antineoplastic agents
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- C07K 2319/00: Fusion polypeptide
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Described herein are compositions and methods of treatment for identifying and clearing cell types expressing particular cell surface markers. In one embodiment, the composition comprises a polypeptide construct that selectively binds a J-configuration of CD277 on a target cell, wherein said polypeptide construct is expressed in an engineered cell.

## Claims

### Claim at position 1

-187. (canceled)

### Claim 188

A pharmaceutical composition comprising a polypeptide construct that selectively binds a J-configuration of CD277 on a target cell, and wherein said polypeptide construct is expressed in cell.

### Claim 189 (depends on 188)

The pharmaceutical composition of claim 188, wherein said CD277 is present as a dimer.

### Claim 190 (depends on 188)

The pharmaceutical composition of claim 188, wherein the polypeptide construct binds the J-configuration of CD277 with higher selectivity as compared to a CD277 molecule which is not in said J-configuration.

### Claim 191 (depends on 188)

The pharmaceutical composition of claim 188, wherein the target cell is a cancer cell.

### Claim 192 (depends on 191)

The pharmaceutical composition of claim 191, wherein the cancer cell is a leukemia cell or from a solid cancer.

### Claim 193

Method of treating cancer in a subject comprising providing to the subject an effective amount of a pharmaceutical composition comprising a polypeptide construct that selectively binds a J-configuration of CD277 on a target cell, and wherein said polypeptide construct is expressed in cell.

### Claim 194 (depends on 193)

Method of claim 193, wherein the cancer is a leukemia or a solid cancer.

### Claim 195 (depends on 193)

Method of claim 193, wherein the subject has cancer cells that are CD277 positive.

### Claim 196 (depends on 193)

Method of claim 193, comprising administering an agent that increases activity of RhoB GTPase in a cancer cell and a dosage form of an agent that increases activity of a phosphoantigen in said cancer cell.

### Claim 197 (depends on 193)

Method of claim 193, wherein the agent that increases activity of a RhoB GTPase performs by indirectly or directly binding said RhoB GTPase and/or wherein the agent that increases activity of a phosphoantigen performs by indirectly or directly binding said phosphoantigen.

### Claim 198 (depends on 193)

Method of claim 193, in a subject having cancer cells that are CD277 positive, comprising administering to the subject an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable agent that selectively binds to the J-configuration of CD277 on said cancer cell.

### Claim 199 (depends on 193)

Method of claim 193, wherein formation of said J-configuration requires at least an interaction of RhoB with CD277 and/or compartimentalization of CD277.

### Claim 200 (depends on 198)

Method of claim 198, wherein said formation of said J-configuration requires interaction of intracellular phosphoantigen with CD277 subsequent to said interaction of RhoB with CD277.

### Claim 201

A method of predicting a positive therapeutic response in a subject to treatment with a polypeptide construct capable of recognizing CD277, or an engineered cell expressing the polypeptide construct, the method comprising steps a) and b) or steps c), d) and e):
a) identifying target cells of the patient as having a nucleotide sequence polymorphism associated with the activity of RhoB; and
b) predicting the subject to exhibit the positive therapeutic response based on said identifying the target cells as having the nucleotide sequence polymorphism,
or
c) obtaining from the subject target cells expressing the CD277 molecule;
d) identifying a J-configuration of the CD277 molecule expressed in the target cells; and
e) predicting the subject to exhibit the positive therapeutic response based on said identifying the J-configuration of the CD277 molecule.

### Claim 202 (depends on 201)

A method according to claim 201, wherein the polypeptide construct recognizes a J-configuration of CD277.

### Claim 203 (depends on 201)

A method according to claim 201, wherein one or more of the target cells is a cancer cells.

### Claim 204 (depends on 201)

A method according to claim 201, wherein said activity is high compared to a RhoB activity in a subject lacking the nucleotide sequence polymorphism.

### Claim 205 (depends on 201)

A method according to claim 201, further comprising the step of predicting a poor therapeutic response in a second subject based on identifying target cells of the second subject as lacking the nucleotide sequence polymorphism.
